News & Updates

Show Multimedia Only

Guselkumab yields durable benefit in biologic-naïve PsA patients

23 Nov 2021

The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.

23 Nov 2021

Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis

22 Nov 2021

Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.

22 Nov 2021

Colchicine cessation possible in familial Mediterranean fever with prolonged remission

21 Nov 2021

Colchicine therapy may be discontinued after prolonged remission in some children with familial Mediterranean fever (FMF), suggests a study, noting, however, that patients with arthritis or myalgia are prone to an attack following treatment cessation.

21 Nov 2021

Belimumab benefit sustained regardless of lupus nephritis status

15 Nov 2021 by

The recombinant human IgG-1λ monoclonal antibody belimumab improved renal outcomes in patients with relapsed and newly diagnosed* active lupus nephritis (LN), according to subgroup analysis results of the BLISS-LN** trial presented at ASN 2021.

15 Nov 2021

Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain

13 Nov 2021

About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.